• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Johnson & Johnson (NY: JNJ )

    155.17 -0.33 (-0.21%)
    Official Closing Price Updated: 4:10 PM EST, Nov 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 7,697,396
    Open 155.90
    Bid (Size) 155.00 (5)
    Ask (Size) 155.39 (1)
    Prev. Close 155.50
    Today's Range 154.11 - 157.12
    52wk Range 143.13 - 168.85
    Shares Outstanding 2,628,679,824
    Dividend Yield 3.20%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity
    Via Benzinga
    Price Over Earnings Overview: Johnson & Johnson
    Via Benzinga

    Performance

    YTD
    -3.00%
    -3.00%
    1 Month
    -5.07%
    -5.07%
    3 Month
    -4.42%
    -4.42%
    6 Month
    +3.65%
    +3.65%
    1 Year
    +2.88%
    +2.88%

    More News

    Read More
    ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
    Via MarketBeat
    This Is What Whales Are Betting On Johnson & Johnson
    Via Benzinga
    This Johnson & Johnson Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
    Via Benzinga
    Trump Taps RFK Jr. For Health Secretary Role, Sends 5 Vaccine Stocks Lower
    Via Benzinga
    Topics Government
    Exposures Political
    Industry Comparison: Evaluating Johnson & Johnson Against Competitors In Pharmaceuticals Industry
    Via Benzinga
    Comparative Study: Johnson & Johnson And Industry Competitors In Pharmaceuticals Industry
    Via Benzinga
    Cidara Therapeutics' Unique Cloudbreak Platform And Its Promise In Influenza And Oncology
    Via Talk Markets
    Why Are These 3 Vanguard ETFs Underperforming the S&P 500 Since Election Day?
    Via The Motley Fool
    Topics ETFs Stocks
    Exposures US Equities
    Johnson & Johnson Challenges Government Drug Pricing Dispute Over Two Drugs
    Via Benzinga
    Topics Lawsuit
    Exposures Financial Legal
    Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever
    Via The Motley Fool
    Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
    Via Benzinga
    Peering Into Johnson & Johnson's Recent Short Interest
    Via Benzinga
    Discover the 3 Best-Performing Biotech IPO Stocks of 2024
    Via MarketBeat
    Topics Initial Public Offering
    Exposures Securities Market
    Empower 2024 Delivers Groundbreaking Insights and Innovation to Achieve Data-Driven Healthcare
    From Inovalon Holdings, Inc.
    Via GlobeNewswire
    Global Psychedelic Drugs Market Expected To Reach $10.2B By 2028 Amid Growing Mental Health Crises
    Via Benzinga
    Johnson & Johnson's Tremfya Seeks Expanded Use Approval After It Shares Encouraging Late-Stage Study Data In Crohn's Disease
    Via Benzinga
    3 Dividend Growth Stocks You Can Buy and Hold Forever
    Via The Motley Fool
    Johnson & Johnson's Blockbuster Drug Tremfya Clears Plaque Psoriasis With Lesions Covering Body's Smaller Areas
    Via Benzinga
    Meet the Only 2 Game-Changing Businesses With a Higher Credit Rating Than the U.S. Government
    Via The Motley Fool
    3 Simple Vanguard ETFs to Buy With $1,000 and Hold for a Lifetime
    Via The Motley Fool
    Topics ETFs
    This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock
    Via The Motley Fool
    Justice Department's Trustee Program Alleges Johnson & Johnson's Talc Litigation Bankruptcy Bid Is Bad-Faith Tactic To Avoid Liability
    Via Benzinga
    Topics Bankruptcy Lawsuit
    Exposures Financial Legal
    Starboard Hammers Pfizer Execs For Failing To Deliver On 'Best Pipeline' Promises
    Via Investor's Business Daily
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.